PCSK9 peptide vaccine

A PCSK9 peptide vaccine is a novel immunotherapeutic approach designed to elicit antibody responses against **proprotein convertase subtilisin/kexin type 9 (PCSK9)**, a protein largely produced by the liver that negatively regulates LDL cholesterol (LDL-C) homeostasis by mediating the internalization and degradation of LDL receptors (LDLR)[3][5]. These vaccines consist of one or more synthetic peptides (sometimes with targeted amino acid substitutions) derived from the PCSK9 protein, often presented on a carrier (such as virus-like particles or nanoliposomes) and administered with adjuvants to enhance immunogenicity[3][4][7]. Antibodies generated by vaccination inhibit the PCSK9/LDLR interaction, leading to increased LDLR availability and reduced LDL-C levels, with demonstrated efficacy in animal models and early clinical studies[1][6][7][8]. Major approaches include VXX-401, AT04A, AT06A, PCSK9Qβ-003, L-IFPTA+, and HIT01. The vaccines are primarily being developed for **hypercholesterolemia** and **atherosclerotic cardiovascular disease**, with promising safety and efficacy profiles in preclinical and phase I trials[3][4][5][6][7][8].

Other names

PCSK9 peptide vaccinePCSK-9 peptide vaccinePCSK 9 peptide vaccineantiPCSK9 vaccineantiPCSK-9 vaccineantiPCSK 9 vaccinePCSK9 VLP vaccinePCSK-9 VLP vaccinePCSK 9 VLP vaccinePCSK9 nanoliposomal vaccinePCSK-9 nanoliposomal vaccinePCSK 9 nanoliposomal vaccine